The global inhalation anaesthesia market size reached a value of more than USD 1.25 Billion in 2024 driven by the increasing prevalence of chronic diseases and medical device manufacturers across the globe. The market is further estimated to grow at a CAGR of 9.40% in the forecast period of 2025-2034.
Base Year
Historical Period
Forecast Period
The growth of the market is driven by the increasing geriatric population and the rise in the prevalence of chronic diseases requiring surgeries.
Integration of artificial intelligence and machine learning algorithms in the anesthesia delivery systems is expected to impact the market value positively.
North America is forecasted to continue to have the largest share of the market due to the increasing incidence of surgeries and well-developed healthcare facilities.
Compound Annual Growth Rate
9.4%
Value in USD Billion
2025-2034
Inhalation Anaesthesia Market Outlook
*this image is indicative*
Inhalation anaesthesia is a clinical procedure used in medical practice to make patients unconscious or numb during surgery. In this method, anaesthetic agents are delivered as gases or volatile agents to the patient via a face mask, or an endotracheal tube placed in the respiratory tract. Some of these anaesthetic agents include nitrous oxide, sevoflurane, isoflurane, and desflurane. When administered in measured proportions, it provides the ideal level of anaesthesia and pain relief without compromising the body’s basic functions. The sedative agents are transported through the respiratory system, lungs, and circulatory system, affecting the patient’s brain and central nervous system. As the incidence rate of chronic diseases that may require surgeries rise, the demand for inhalational anesthesia is likely to increase in coming years.
Increasing Prevalence of Surgical Procedures Fuels Market Growth
The market for surgical procedures is growing due to the increasing application of inhalation anesthesia in from road accidents and emergencies. Global healthcare faces challenges due to the increasing incidence of diseases such as cancer, respiratory illnesses, and gastrointestinal issues. Chronic diseases like cancer, infectious diseases, and genetic disorders are also rising globally. The American Cancer Society reports that cancer contributes significantly to morbidity and mortality, with an estimated about 1,958,310, new cases and 609,820 cancer-related deaths in 2023. This, coupled with the increasing prevalence of chronic diseases, drives market growth for inhalation anesthesia.
Increased Geriatric Population Promoting the Inhalation Anaesthesia Market
The global geriatric population is expected to drive the growth of inhalation anaesthesia due to their high susceptibility to degenerative and chronic diseases. Elderly patients, particularly those with cardiovascular, neurological, respiratory, or degenerative conditions, are more likely to require surgeries and therapeutics. The discomfort of injecting anaesthesia through intravenous routes for elderly patients is a significant factor, which will continue to influence the consistent demand for inhalation anaesthesia in the coming years.
The EMR’s report titled “Inhalation Anaesthesia Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Type
Market Breakup by Application
Market Breakup by Region
Based on Drug Type Sevoflurane to Hold a Substantial Market Share
Based on drug type, the market is segmented into sevoflurane, desflurane, isoflurane, and halothane. Among these, the increasing use of sevoflurane, owing to several benefits including a pleasant odor, rapid induction, reduced postoperative nausea, and minimal cardiac toxicity are driving its market share. Patients with difficult airways or severe bronchospastic disease are increasingly using sevoflurane due to its reduced irritation to mucous membranes and faster recovery. The drug is also used in both inpatient and outpatient surgeries, and its excellent safety record makes it suitable for both adults and pediatric patients. The increasing approvals of sevoflurane by the Food and Drug Administration (FDA) are expected to further stimulate the market development.
Market Breakup Based on Application Set to Witness Market Growth
The global inhalation anaesthesia market, based on applications is divided into inductive and maintenance. Maintenance anaesthesia is expected to dominate the market because it ensures patients remain unconscious during operations. Maintenance anaesthesia also involves administering anaesthetics in progressively regulated dosages, making it useful for long procedures. This constant demand drives companies to upgrade delivery systems for maintenance, focusing on patient safety and improving technologies for tracking anaesthesia depth and reducing complications.
The market report reveals regional trends in North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America is expected to dominate due to rising surgery rates and hospital requirements. Asia Pacific region is experiencing significant growth due to increasing disease prevalence and the elderly population. Inhalation anaesthetic drugs like Sevoflurane and Desflurane are in high demand due to their fast induction and recovery. The market is estimated to witness revenue growth, especially in response to the growing geriatric population in China.
The key features of the market report include patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Established in 1950 and based in Atlanta, Georgia, the key products from this company includes isoflurane USP and Sevoflurane USP, both of which are widely used in human and veterinary medicine. Isoflurane USP is favored for its rapid onset and recovery times, making it a reliable choice for various surgical procedures.
It is a U.S. based company founded in 1931. This company is a leader in the inhalation anaesthesia market. Their product lineup includes Suprane (Desflurane), Forane (Isoflurane), and Sevoflurane.
Founded in 2013 and based in North Chicago, Illinois, the company provides Sevoflurane (marketed as Ultane) as its primary inhalation anaesthetic. Ultane is widely used for its quick induction and emergence properties, making it suitable for both pediatric and adult patients.
The company was founded in Basel, Switzerland in 1886. The company offers a range of inhalation anaesthetics including Desflurane, Sevoflurane, and Isoflurane. It launched Desflurane as a generic version of Suprane, providing a cost-effective option for maintaining anaesthesia during surgeries.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other companies include Piramal Enterprises Ltd., Dechra Pharmaceuticals PLC, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Jiangsu Hengrui Medicine Co. Ltd, Lunan Pharmaceutical Group Co. Ltd, Merck KGaA, and Troikaa Pharmaceuticals Ltd.
Kindly note that this only represents a partial list of companies and the complete list has been in the report.
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Type |
|
| Breakup by Application |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
